Silver Book Fact

A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.

Ravina B, Fagan S, Hart R, Hovinga C, et al. Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment. Neurology. 2003; 60(8): 1234-40. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12707423

Reference

Title
Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment
Publication
Neurology
Publication Date
2003
Authors
Ravina B, Fagan S, Hart R, Hovinga C, et al
Volume & Issue
Volume 60, Issue 8
Pages
1234-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • In one study, despite a 4-fold increase in prescription drug spending, overall health spending for Alzheimer’s patients undergoing drug therapy went down by 1/3.  
  • Studies by the National Center for Complementary and Alternative Medicine (NCCAM) at NIH are looking at the neuroprotective qualities of diets rich in B vitamins and antioxidant phytochemicals. These nutrients…  
  • The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately…  
  • According to the Pharmaceutical Research and Manufacturers of America, 42 medicines are currently in development for Alzheimer’s disease.  
  • 32 drugs are currently in development for Parkinson’s disease.